Cobenfy is a drug owned by Bristol-myers Squibb Co. It is protected by 10 US drug patents filed in 2024 out of which none have expired yet. Cobenfy's patents will be open to challenges from 26 September, 2028. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 27, 2039. Details of Cobenfy's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11890378 | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation |
Sep, 2039
(14 years from now) | Active |
| US11471413 | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation |
Sep, 2039
(14 years from now) | Active |
| US11452692 | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation |
Sep, 2039
(14 years from now) | Active |
| US10933020 | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation |
Sep, 2039
(14 years from now) | Active |
| US10925832 | Compositions and methods for treatment of disorders ameliorated by muscarinic receptor activation |
Sep, 2039
(14 years from now) | Active |
| US10369144 | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
Jul, 2030
(5 years from now) | Active |
| US10369143 | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
Jul, 2030
(5 years from now) | Active |
| US10265311 | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
Jul, 2030
(5 years from now) | Active |
| US10238643 | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
Jul, 2030
(5 years from now) | Active |
| US10695339 | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
Jul, 2030
(5 years from now) | Active |
FDA has granted several exclusivities to Cobenfy. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Cobenfy, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Cobenfy.
Exclusivity Information
Cobenfy holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2029. Details of Cobenfy's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 26, 2029 |
US patents provide insights into the exclusivity only within the United States, but Cobenfy is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Cobenfy's family patents as well as insights into ongoing legal events on those patents.
Cobenfy's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Cobenfy's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Sep 27, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Cobenfy Generics:
There are no approved generic versions for Cobenfy as of now.
Alternative Brands for Cobenfy
There are several other brand drugs in the same treatment category as Cobenfy. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Shandong Luye |
| |||
About Cobenfy
Cobenfy is a drug owned by Bristol-Myers Squibb Co. Cobenfy uses Trospium Chloride; Xanomeline Tartrate as an active ingredient. Cobenfy was launched by Bristol-Myers in 2024.
Approval Date:
Cobenfy was approved by FDA for market use on 26 September, 2024.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Cobenfy is 26 September, 2024, its NCE-1 date is estimated to be 26 September, 2028.
Active Ingredient:
Cobenfy uses Trospium Chloride; Xanomeline Tartrate as the active ingredient. Check out other Drugs and Companies using Trospium Chloride; Xanomeline Tartrate ingredient
Dosage:
Cobenfy is available in capsule form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 20MG;EQ 50MG BASE | CAPSULE | Prescription | ORAL |
| 30MG;EQ 125MG BASE | CAPSULE | Prescription | ORAL |
| 20MG;EQ 100MG BASE | CAPSULE | Prescription | ORAL |